GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (XSAT:SPAG BTA) » Definitions » Cyclically Adjusted PS Ratio

Spago Nanomedical AB (XSAT:SPAG BTA) Cyclically Adjusted PS Ratio : (As of Jul. 23, 2025)


View and export this data going back to . Start your Free Trial

What is Spago Nanomedical AB Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Spago Nanomedical AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Spago Nanomedical AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Cyclically Adjusted PS Ratio Chart

Spago Nanomedical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 111.58 18.67 20.51 14.07

Spago Nanomedical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.79 22.94 15.71 14.07 14.96

Competitive Comparison of Spago Nanomedical AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Spago Nanomedical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Cyclically Adjusted PS Ratio falls into.


;
;

Spago Nanomedical AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Spago Nanomedical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Spago Nanomedical AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.094/132.8245*132.8245
=0.094

Current CPI (Mar. 2025) = 132.8245.

Spago Nanomedical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 0.006 100.751 0.008
201606 0.000 101.019 0.000
201609 0.010 101.138 0.013
201612 0.000 102.022 0.000
201703 0.001 102.022 0.001
201706 0.001 102.752 0.001
201709 0.000 103.279 0.000
201712 0.011 103.793 0.014
201803 0.000 103.962 0.000
201806 0.000 104.875 0.000
201809 0.000 105.679 0.000
201812 0.000 105.912 0.000
201903 0.000 105.886 0.000
201906 0.008 106.742 0.010
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.028 106.563 0.035
202006 0.000 107.498 0.000
202009 0.019 107.635 0.023
202012 0.049 108.296 0.060
202103 0.028 108.360 0.034
202106 0.074 108.928 0.090
202109 0.054 110.338 0.065
202112 0.027 112.486 0.032
202203 0.059 114.825 0.068
202206 0.084 118.384 0.094
202209 0.110 122.296 0.119
202212 0.039 126.365 0.041
202303 0.024 127.042 0.025
202306 0.032 129.407 0.033
202309 0.075 130.224 0.076
202312 0.203 131.912 0.204
202403 0.097 132.205 0.097
202406 0.127 132.716 0.127
202409 0.134 132.304 0.135
202412 0.171 132.987 0.171
202503 0.094 132.825 0.094

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Spago Nanomedical AB  (XSAT:SPAG BTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Spago Nanomedical AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines